NCT02353026View on ClinicalTrials.gov

Phase I Study of Intravenous Artesunate for Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Solid Tumors
Interventions
DRUG

Intravenous Artesunate

Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Georgetown University

OTHER

NCT02353026 - Phase I Study of Intravenous Artesunate for Solid Tumors | Biotech Hunter | Biotech Hunter